Antabio is a privately-held clinical stage biopharmaceutical company developing novel and highly differentiated antibacterial treatments of drug-resistant infections due to WHO critical priority pathogens, with a particular focus on life-threatening respiratory infections.

Antabio has one of the best teams in the industry featuring former management and executives from Novexel, GSK, Merck and AstraZeneca with track-records in anti-infective drug development, licensing and M&A. The company has an impressive track-record in attracting non-dilutive funding, including multi-million € awards from the Wellcome Trust, CARB-X, the French Government (ARPEGE), and the European Union (EIC Accelerator).

Antabio’s portfolio includes MEM-ANT3310, which combines the well-known carbapenem meropenem (MEM) with ANT3310, Antabio’s breakthrough serine-beta-lactamase (SBL) inhibitor. MEM-ANT3310 provides a unique coverage of priority Gram-negative pathogens frequently encountered in life-threatening infections such as Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP). Phase 1a clinical study has recently been completed.

Their portfolio also includes ANT3273, a groundbreaking (novel class, novel mode of action) inhaled drug targeting the LasB elastase of Pseudomonas aeruginosa (PA), a key virulence factor associated with increased lung pathology severity and worse outcomes in PA-infected patients, such as bronchiectasis, cystic fibrosis, asthma and COPD.

–  Therapeutic areas: Infectious diseases, Urinary Tract Infection, Respiratory Tract Infection, Multidrug resistant infection, Bacterial infection, Gram negative bacterium infection, Lung infection, Bacterial Pneumonia, Bronchiectasis, Cystic Fibrosis

–  Based in: Labège (FRANCE)

–  Employees: 11 – 50

–  Created in: 2009